Cargando…

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy

In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted therapies. However, not all cancer patients benefit from single or combination therapy with anti-CTLA-4 and anti-PD-1/PD-L1 mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Letong, Li, Yuchen, Tan, Jiaxiong, Xu, Ling, Li, Yangqiu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478462/ https://www.ncbi.nlm.nih.gov/pubmed/37670328 http://dx.doi.org/10.1186/s13045-023-01499-1

Ejemplares similares

Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting
por: Tan, Jiaxiong, et al.
Publicado: (2023)

The Role of TIM-3 and LAG-3 in the Microenvironment and Immunotherapy of Ovarian Cancer
por: Kozłowski, Mateusz, et al.
Publicado: (2022)

Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy
por: Takamatsu, Kimiharu, et al.
Publicado: (2021)

Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma
por: Huang, Shuxin, et al.
Publicado: (2022)

TIM-3 in Leukemia; Immune Response and Beyond
por: Rezaei, Mahnaz, et al.
Publicado: (2021)

TIM-3, a promising target for cancer immunotherapy
por: He, Yayi, et al.
Publicado: (2018)

TIGIT in cancer immunotherapy
por: Chauvin, Joe-Marc, et al.
Publicado: (2020)

TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action
por: Du, Wenwen, et al.
Publicado: (2017)

Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development
por: Rotte, Anand, et al.
Publicado: (2021)

High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer
por: Mollavelioglu, Baran, et al.
Publicado: (2022)

Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML
por: Tan, Jiaxiong, et al.
Publicado: (2020)

New emerging targets in cancer immunotherapy: the role of TIM3
por: Friedlaender, Alex, et al.
Publicado: (2019)

Immune Co-inhibitory Receptors CTLA-4, PD-1, TIGIT, LAG-3, and TIM-3 in Upper Tract Urothelial Carcinomas: A Large Cohort Study
por: Jin, Shengming, et al.
Publicado: (2023)

High Co-Expression of PDCD1/TIGIT/CD47/KIR3DL2 in Bone Marrow Is Associated with Poor Prognosis for Patients with Myelodysplastic Syndrome
por: Zhong, Mengjun, et al.
Publicado: (2023)

DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer
por: Sasidharan Nair, Varun, et al.
Publicado: (2018)

New emerging targets in cancer immunotherapy: the role of LAG3
por: Puhr, Hannah Christina, et al.
Publicado: (2019)

Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
por: Marcq, Elly, et al.
Publicado: (2017)

Tissue-Specific Expression of TIGIT, PD-1, TIM-3, and CD39 by γδ T Cells in Ovarian Cancer
por: Weimer, Pauline, et al.
Publicado: (2022)

TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors
por: Sauer, Natalia, et al.
Publicado: (2023)

Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy
por: Wang, Daijun, et al.
Publicado: (2022)

DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer
por: Sasidharan Nair, Varun, et al.
Publicado: (2018)

Fc-competent multispecific PDL-1/TIGIT/LAG-3 antibodies potentiate superior anti-tumor T cell response
por: Yang, Riyao, et al.
Publicado: (2023)

TIMs, TAMs, and PS- antibody targeting: implications for cancer immunotherapy
por: Dayoub, Adam S., et al.
Publicado: (2020)

A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy
por: Kuang, Zhihui, et al.
Publicado: (2020)

Tim-3 signaling blockade with α-lactose induces compensatory TIGIT expression in Plasmodium berghei ANKA-infected mice
por: Zhang, Yiwei, et al.
Publicado: (2019)

Immune checkpoint alterations and their blockade in COVID-19 patients
por: Tan, Jiaxiong, et al.
Publicado: (2022)

LAG3 and its emerging role in cancer immunotherapy
por: Wang, Miao, et al.
Publicado: (2021)

CD4(+) T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART
por: Fromentin, Rémi, et al.
Publicado: (2016)

The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?
por: Ganjalikhani Hakemi, Mazdak, et al.
Publicado: (2020)

Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma
por: Wang, Peipei, et al.
Publicado: (2021)

Expression of Immune Checkpoint Regulators IDO, VISTA, LAG3, and TIM3 in Resected Pancreatic Ductal Adenocarcinoma
por: Popp, Felix C., et al.
Publicado: (2021)

Tim-3 finds its place in the cancer immunotherapy landscape
por: Acharya, Nandini, et al.
Publicado: (2020)

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)
por: De Giglio, Andrea, et al.
Publicado: (2021)

Immune Checkpoint Profiling in Humanized Breast Cancer Mice Revealed Cell-Specific LAG-3/PD-1/TIM-3 Co-Expression and Elevated PD-1/TIM-3 Secretion
por: Bruss, Christina, et al.
Publicado: (2023)

The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy
por: Long, Long, et al.
Publicado: (2018)

TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies
por: Jin, Shenhe, et al.
Publicado: (2022)

The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3
por: Marcq, Elly, et al.
Publicado: (2021)

Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer
por: Martinez, Marina, et al.
Publicado: (2021)

TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy
por: Chiang, Eugene Y, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ctunc5bg6oba3ank8uo7a72rdt